Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Myalgic Encephalomyelitis /Chronic Fatigue Syndrome (ME/CFS) is a chronic condition without a diagnostic test and some 80 - 90% of patients remain un-diagnosed. A new paper published in Frontiers in Medicine outlines how having a diagnostic test could greatly help both patients and medics.

Biomarker illustration with text 'Propelling research, providing hope, preserving dignity'

ME/CFS is a devastating disease that affects over 250,0001 individuals in the UK, yet there is no reliable biomarker and diagnosis is based on manifesting clinical symptoms, coupled with high inter-patient variability. 

Developing an early diagnostic test is of fundamental importance in the treatment of any illness. In ME/CFS a diagnostic test would help not only in the clinical management of patients and but give patients hope that we are moving closer to understanding a condition which is currently is very much a mystery illness.

Using modern statistical approaches and machine learning Dr Karl Morten (Nuffield Department of Women's and Reproductive Health) and his colleagues have identified a series of variables including the micro RNA’s of blood cells and small extracellular vesicles which can distinguish a group of severe ME/CFS patients from healthy controls with 100% accuracy. These two groups cannot be readily separated by a standard blood test. Standard tests return as negative for the severely ill group. Their next step is to apply this approach to mild and moderately affected ME/CFS patients with different levels of disability and compare to other disease groups as well as healthy controls. This will determine if we have a potential panel of biomarkers which could be used to developed a diagnostic test. 

Read the full story on the Nuffield Department of Women's and Reproductive Health website

 

Similar stories

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

New blood test could save lives of heart attack victims

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Gero Miesenböck awarded 2023 Japan Prize

Congratulations to Professor Gero Miesenböck, Department of Physiology, Anatomy and Genetics (DPAG), who has been awarded the 2023 Japan Prize in the field of Life Sciences, together with Professor Karl Deisseroth, for pioneering work in the field of optogenetics.